Stay updated on Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision history now includes a new version v3.5.2 and removes the older v3.5.0.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedNew revision entry added: v3.5.0. The previous revision v3.4.3 is listed as deleted.SummaryDifference0.1%

- Check46 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page footer.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision: v3.4.2 was added to the study record history, and Revision: v3.4.1 was removed. This is a minor update to release notes and does not alter the study information.SummaryDifference0.9%

- Check81 days agoChange DetectedA site-wide funding-status notice was added and the site version updated from v3.4.0 to v3.4.1.SummaryDifference0.9%

- Check88 days agoChange DetectedUI enhancements include a Show glossary option and color-coded highlights for additions (green) and deletions (red) in the record history. The revision banner now displays Revision: v3.4.0.SummaryDifference1%

Stay in the know with updates to Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax, Azacitidine, Lintuzumab-Ac225 in AML Patients Clinical Trial page.